Drug Search Results
More Filters [+]

Esmirtazapine

Alternative Names: esmirtazapine
Latest Update: 2024-05-11
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ADRA2 Antagonist,5-HT2 Inverse Agonist,H1 Inverse Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Esmirtazapine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Insomnia|Menopause|Sleep Disorders, Intrinsic|Parasomnias|Dyssomnias

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

176003/P05721/MK-8265-007

P3

Terminated

Dyssomnias|Insomnia|Sleep Disorders, Intrinsic|Parasomnias

2010-03-10

JADE

P3

Completed

Insomnia

2010-02-19

Jade

P3

Completed

Insomnia|Dyssomnias|Sleep Disorders, Intrinsic|Parasomnias

2010-02-14

P05709

P3

Completed

Dyssomnias|Insomnia

2009-12-21

Recent News Events